Search results
Results from the WOW.Com Content Network
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
For premium support please call: 800-290-4726 more ways to reach us
AMGen corporate logo, 1983 Argentine president Mauricio Macri meets with heads of Amgen, in 2018. Amgen was established in Thousand Oaks in 1980, as Applied Molecular Genetics. [6] [7] Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin. [8]
Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), is a United States Supreme Court case in which the Court held that Amgen's two patent applications on cholesterol-lowering drugs failed to satisfy the enablement clause of §112 of the Patent Act, 35 U.S.C. § 112(a).
Amgen (NASDAQ: AMGN) Q4 2024 Earnings Call Feb 04, 2025, 4:30 p.m. ET. Contents: ... which is let's start from 10 products with double-digit growth in 2024 over 2023, 14 products annualizing -- or ...
Alan J. Russell (born August 8, 1962 in Salford, Greater Manchester UK), is Vice President of Biologics for Amgen, one of the world’s leading Biopharmaceutical companies. Until 2020, Alan was the Highmark Distinguished Career Professor and Director of the Disruptive Health Technology Institute at Carnegie Mellon University .
A while back, I argued that Amgen still had room to run based on its strong pipeline, financial position, and comparative valuation. The acquisition of Onyx was a major step in accomplishing those ...
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [8] [9] Epoetin alfa is an erythropoiesis-stimulating agent. [8]